APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs Used for Treating Primary Aldosteronism

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs Used for Treating Primary Aldosteronism Market Analysis and Forecast 2026-2032

29 December 2025210 pages

Choose your research edition.

Industry ResearchDrugs Used for Treating Primary Aldosteronism Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs Used for Treating Primary Aldosteronism Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Drugs Used for Treating Primary Aldosteronism Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs Used for Treating Primary Aldosteronism Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs Used for Treating Primary Aldosteronism Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Drugs Used for Treating Primary Aldosteronism market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs Used for Treating Primary Aldosteronism is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs Used for Treating Primary Aldosteronism is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs Used for Treating Primary Aldosteronism is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs Used for Treating Primary Aldosteronism is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Drugs Used for Treating Primary Aldosteronism include Chongqing Kerui Pharmaceutical, Jiangsu Chia Tai Fenghai Pharmaceutical, Grand Pharmaceutical, Yatai Pharma, Suzhou Homesun Pharmaceutical, Shanghai Xinyi Wanxiang pharmaceutical, Jiangsu Changjiang Pharmaceutical, Jiangsu Yunyang Pharmaceutical Group and Hangzhou Minsheng Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs Used for Treating Primary Aldosteronism, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs Used for Treating Primary Aldosteronism, also provides the sales of main regions and countries. Of the upcoming market potential for Drugs Used for Treating Primary Aldosteronism, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs Used for Treating Primary Aldosteronism sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs Used for Treating Primary Aldosteronism market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Drugs Used for Treating Primary Aldosteronism sales, projected growth trends, production technology, application and end-user industry.

Drugs Used for Treating Primary Aldosteronism Segment by Company

Chongqing Kerui Pharmaceutical

Jiangsu Chia Tai Fenghai Pharmaceutical

Grand Pharmaceutical

Yatai Pharma

Suzhou Homesun Pharmaceutical

Shanghai Xinyi Wanxiang pharmaceutical

Jiangsu Changjiang Pharmaceutical

Jiangsu Yunyang Pharmaceutical Group

Hangzhou Minsheng Pharmaceutical

Sinopharm Zhonglian Pharmaceutical

Zydus

Viatris Pharmaceuticals

Sun Pharmaceuticals

Sandoz

Pfizer

Mylan

MSN

Kyorin Rimedio

Camber Pharmaceuticals

Amneal Pharmaceuticals

Actavis Elizabeth

Accord Healthcare

Drugs Used for Treating Primary Aldosteronism Segment by Type

Spironolactone

Eplerenone

Other

Drugs Used for Treating Primary Aldosteronism Segment by Application

Hospital and Clinic

Pharmacy

Other

Drugs Used for Treating Primary Aldosteronism Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Used for Treating Primary Aldosteronism market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs Used for Treating Primary Aldosteronism and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Used for Treating Primary Aldosteronism.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Drugs Used for Treating Primary Aldosteronism in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Drugs Used for Treating Primary Aldosteronism manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs Used for Treating Primary Aldosteronism sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs Used for Treating Primary Aldosteronism Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Spironolactone Major Manufacturers Table 3. Eplerenone Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Drugs Used for Treating Primary Aldosteronism Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital and Clinic Major Manufacturers Table 7. Pharmacy Major Manufacturers Table 8. Other Major Manufacturers Table 9. Drugs Used for Treating Primary Aldosteronism Industry Trends Table 10. Drugs Used for Treating Primary Aldosteronism Industry Drivers Table 11. Drugs Used for Treating Primary Aldosteronism Industry Opportunities and Challenges Table 12. Drugs Used for Treating Primary Aldosteronism Industry Restraints Table 13. Global Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Drugs Used for Treating Primary Aldosteronism Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Drugs Used for Treating Primary Aldosteronism Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Region (2021-2026) Table 17. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Region (2027-2032) Table 18. Global Drugs Used for Treating Primary Aldosteronism Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Drugs Used for Treating Primary Aldosteronism Sales by Region (2021-2026) & (K Units) Table 20. Global Drugs Used for Treating Primary Aldosteronism Sales by Region (2027-2032) & (K Units) Table 21. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Region (2021-2026) Table 22. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Region (2027-2032) Table 23. Global Drugs Used for Treating Primary Aldosteronism Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Drugs Used for Treating Primary Aldosteronism Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Manufacturers (2021-2026) Table 27. Global Drugs Used for Treating Primary Aldosteronism Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Drugs Used for Treating Primary Aldosteronism Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Drugs Used for Treating Primary Aldosteronism Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Drugs Used for Treating Primary Aldosteronism Manufacturers, Product Type & Application Table 31. Global Drugs Used for Treating Primary Aldosteronism Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Drugs Used for Treating Primary Aldosteronism by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Drugs Used for Treating Primary Aldosteronism Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Type (2021-2026) Table 38. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Type (2027-2032) Table 39. Global Drugs Used for Treating Primary Aldosteronism Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 41. Global Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 42. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Type (2021-2026) Table 43. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Type (2027-2032) Table 44. Global Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2026) & (US$/Unit) Table 45. Global Drugs Used for Treating Primary Aldosteronism Price by Type (2027-2032) & (US$/Unit) Table 46. Global Drugs Used for Treating Primary Aldosteronism Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Application (2021-2026) Table 50. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Application (2027-2032) Table 51. Global Drugs Used for Treating Primary Aldosteronism Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 53. Global Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 54. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Application (2021-2026) Table 55. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Application (2027-2032) Table 56. Global Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2026) & (US$/Unit) Table 57. Global Drugs Used for Treating Primary Aldosteronism Price by Application (2027-2032) & (US$/Unit) Table 58. Chongqing Kerui Pharmaceutical Company Information Table 59. Chongqing Kerui Pharmaceutical Business Overview Table 60. Chongqing Kerui Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Chongqing Kerui Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 62. Chongqing Kerui Pharmaceutical Recent Development Table 63. Jiangsu Chia Tai Fenghai Pharmaceutical Company Information Table 64. Jiangsu Chia Tai Fenghai Pharmaceutical Business Overview Table 65. Jiangsu Chia Tai Fenghai Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Jiangsu Chia Tai Fenghai Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 67. Jiangsu Chia Tai Fenghai Pharmaceutical Recent Development Table 68. Grand Pharmaceutical Company Information Table 69. Grand Pharmaceutical Business Overview Table 70. Grand Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Grand Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 72. Grand Pharmaceutical Recent Development Table 73. Yatai Pharma Company Information Table 74. Yatai Pharma Business Overview Table 75. Yatai Pharma Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Yatai Pharma Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 77. Yatai Pharma Recent Development Table 78. Suzhou Homesun Pharmaceutical Company Information Table 79. Suzhou Homesun Pharmaceutical Business Overview Table 80. Suzhou Homesun Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Suzhou Homesun Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 82. Suzhou Homesun Pharmaceutical Recent Development Table 83. Shanghai Xinyi Wanxiang pharmaceutical Company Information Table 84. Shanghai Xinyi Wanxiang pharmaceutical Business Overview Table 85. Shanghai Xinyi Wanxiang pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shanghai Xinyi Wanxiang pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 87. Shanghai Xinyi Wanxiang pharmaceutical Recent Development Table 88. Jiangsu Changjiang Pharmaceutical Company Information Table 89. Jiangsu Changjiang Pharmaceutical Business Overview Table 90. Jiangsu Changjiang Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Jiangsu Changjiang Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 92. Jiangsu Changjiang Pharmaceutical Recent Development Table 93. Jiangsu Yunyang Pharmaceutical Group Company Information Table 94. Jiangsu Yunyang Pharmaceutical Group Business Overview Table 95. Jiangsu Yunyang Pharmaceutical Group Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Jiangsu Yunyang Pharmaceutical Group Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 97. Jiangsu Yunyang Pharmaceutical Group Recent Development Table 98. Hangzhou Minsheng Pharmaceutical Company Information Table 99. Hangzhou Minsheng Pharmaceutical Business Overview Table 100. Hangzhou Minsheng Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hangzhou Minsheng Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 102. Hangzhou Minsheng Pharmaceutical Recent Development Table 103. Sinopharm Zhonglian Pharmaceutical Company Information Table 104. Sinopharm Zhonglian Pharmaceutical Business Overview Table 105. Sinopharm Zhonglian Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sinopharm Zhonglian Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 107. Sinopharm Zhonglian Pharmaceutical Recent Development Table 108. Zydus Company Information Table 109. Zydus Business Overview Table 110. Zydus Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Zydus Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 112. Zydus Recent Development Table 113. Viatris Pharmaceuticals Company Information Table 114. Viatris Pharmaceuticals Business Overview Table 115. Viatris Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Viatris Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 117. Viatris Pharmaceuticals Recent Development Table 118. Sun Pharmaceuticals Company Information Table 119. Sun Pharmaceuticals Business Overview Table 120. Sun Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sun Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 122. Sun Pharmaceuticals Recent Development Table 123. Sandoz Company Information Table 124. Sandoz Business Overview Table 125. Sandoz Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Sandoz Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 127. Sandoz Recent Development Table 128. Pfizer Company Information Table 129. Pfizer Business Overview Table 130. Pfizer Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Pfizer Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 132. Pfizer Recent Development Table 133. Mylan Company Information Table 134. Mylan Business Overview Table 135. Mylan Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Mylan Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 137. Mylan Recent Development Table 138. MSN Company Information Table 139. MSN Business Overview Table 140. MSN Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. MSN Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 142. MSN Recent Development Table 143. Kyorin Rimedio Company Information Table 144. Kyorin Rimedio Business Overview Table 145. Kyorin Rimedio Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Kyorin Rimedio Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 147. Kyorin Rimedio Recent Development Table 148. Camber Pharmaceuticals Company Information Table 149. Camber Pharmaceuticals Business Overview Table 150. Camber Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Camber Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 152. Camber Pharmaceuticals Recent Development Table 153. Amneal Pharmaceuticals Company Information Table 154. Amneal Pharmaceuticals Business Overview Table 155. Amneal Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Amneal Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 157. Amneal Pharmaceuticals Recent Development Table 158. Actavis Elizabeth Company Information Table 159. Actavis Elizabeth Business Overview Table 160. Actavis Elizabeth Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Actavis Elizabeth Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 162. Actavis Elizabeth Recent Development Table 163. Accord Healthcare Company Information Table 164. Accord Healthcare Business Overview Table 165. Accord Healthcare Drugs Used for Treating Primary Aldosteronism Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Accord Healthcare Drugs Used for Treating Primary Aldosteronism Product Portfolio Table 167. Accord Healthcare Recent Development Table 168. North America Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 169. North America Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 170. North America Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 171. North America Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 172. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2021-2026) & (US$/Unit) Table 173. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2027-2032) & (US$/Unit) Table 174. North America Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 175. North America Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 176. North America Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 177. North America Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 178. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2021-2026) & (US$/Unit) Table 179. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2027-2032) & (US$/Unit) Table 180. North America Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. North America Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 182. North America Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 183. North America Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 184. North America Drugs Used for Treating Primary Aldosteronism Sales by Country (2021-2026) & (K Units) Table 185. North America Drugs Used for Treating Primary Aldosteronism Sales by Country (2027-2032) & (K Units) Table 186. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2021-2026) & (US$/Unit) Table 187. North America Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2027-2032) & (US$/Unit) Table 188. United States Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 189. Canada Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 190. Mexico Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 191. Europe Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 192. Europe Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 193. Europe Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 194. Europe Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 195. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2021-2026) & (US$/Unit) Table 196. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2027-2032) & (US$/Unit) Table 197. Europe Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 198. Europe Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 199. Europe Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 200. Europe Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 201. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2021-2026) & (US$/Unit) Table 202. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2027-2032) & (US$/Unit) Table 203. Europe Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. Europe Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. Europe Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. Europe Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. Europe Drugs Used for Treating Primary Aldosteronism Sales by Country (2021-2026) & (K Units) Table 208. Europe Drugs Used for Treating Primary Aldosteronism Sales by Country (2027-2032) & (K Units) Table 209. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2021-2026) & (US$/Unit) Table 210. Europe Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Germany Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 212. France Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 213. U.K. Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 214. Italy Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 215. Russia Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 216. Spain Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 217. Netherlands Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 218. Switzerland Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 219. Sweden Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 220. Poland Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 221. China Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 222. China Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 223. China Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 224. China Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 225. China Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2021-2026) & (US$/Unit) Table 226. China Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2027-2032) & (US$/Unit) Table 227. China Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 228. China Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 229. China Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 230. China Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 231. China Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2021-2026) & (US$/Unit) Table 232. China Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2027-2032) & (US$/Unit) Table 233. Asia Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 234. Asia Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 235. Asia Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 236. Asia Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 237. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2021-2026) & (US$/Unit) Table 238. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2027-2032) & (US$/Unit) Table 239. Asia Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 240. Asia Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 241. Asia Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 242. Asia Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 243. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2021-2026) & (US$/Unit) Table 244. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2027-2032) & (US$/Unit) Table 245. Asia Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 246. Asia Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 247. Asia Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 248. Asia Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 249. Asia Drugs Used for Treating Primary Aldosteronism Sales by Country (2021-2026) & (K Units) Table 250. Asia Drugs Used for Treating Primary Aldosteronism Sales by Country (2027-2032) & (K Units) Table 251. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2021-2026) & (US$/Unit) Table 252. Asia Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2027-2032) & (US$/Unit) Table 253. Japan Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 254. South Korea Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 255. India Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 256. Australia Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 257. Taiwan Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 258. Southeast Asia Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 259. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2026) & (US$ Million) Table 260. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Type (2027-2032) & (US$ Million) Table 261. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2026) & (K Units) Table 262. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Type (2027-2032) & (K Units) Table 263. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2021-2026) & (US$/Unit) Table 264. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Type (2027-2032) & (US$/Unit) Table 265. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2026) & (US$ Million) Table 266. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Application (2027-2032) & (US$ Million) Table 267. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2026) & (K Units) Table 268. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Application (2027-2032) & (K Units) Table 269. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2021-2026) & (US$/Unit) Table 270. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Application (2027-2032) & (US$/Unit) Table 271. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 272. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 273. SAMEA Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 274. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 275. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Country (2021-2026) & (K Units) Table 276. SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Country (2027-2032) & (K Units) Table 277. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2021-2026) & (US$/Unit) Table 278. SAMEA Drugs Used for Treating Primary Aldosteronism Sales Price by Country (2027-2032) & (US$/Unit) Table 279. Brazil Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 280. Argentina Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 281. Chile Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 282. Colombia Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 283. Peru Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 284. Saudi Arabia Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 285. Israel Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 286. UAE Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 287. Turkey Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 288. Iran Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 289. Egypt Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Table 290. Key Raw Materials Table 291. Raw Materials Key Suppliers Table 292. Drugs Used for Treating Primary Aldosteronism Distributors List Table 293. Drugs Used for Treating Primary Aldosteronism Customers List Table 294. Research Programs/Design for This Report Table 295. Authors List of This Report Table 296. Secondary Sources Table 297. Primary Sources List of Figures Figure 1. Drugs Used for Treating Primary Aldosteronism Image Figure 2. Global Drugs Used for Treating Primary Aldosteronism Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs Used for Treating Primary Aldosteronism Market Size Share 2021 VS 2025 VS 2032 Figure 4. Spironolactone Image Figure 5. Eplerenone Image Figure 6. Other Image Figure 7. Global Drugs Used for Treating Primary Aldosteronism Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs Used for Treating Primary Aldosteronism Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital and Clinic Image Figure 10. Pharmacy Image Figure 11. Other Image Figure 12. Global Drugs Used for Treating Primary Aldosteronism Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Drugs Used for Treating Primary Aldosteronism Revenue (2021-2032) & (US$ Million) Figure 14. Global Drugs Used for Treating Primary Aldosteronism Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Region (2021-2032) Figure 17. Global Drugs Used for Treating Primary Aldosteronism Sales (2021-2032) & (K Units) Figure 18. Global Drugs Used for Treating Primary Aldosteronism Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Drugs Used for Treating Primary Aldosteronism Sales YoY (2021-2032) & (K Units) Figure 21. Europe Drugs Used for Treating Primary Aldosteronism Sales YoY (2021-2032) & (K Units) Figure 22. China Drugs Used for Treating Primary Aldosteronism Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Drugs Used for Treating Primary Aldosteronism Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Drugs Used for Treating Primary Aldosteronism Sales YoY (2021-2032) & (K Units) Figure 25. Global Drugs Used for Treating Primary Aldosteronism Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Drugs Used for Treating Primary Aldosteronism Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Drugs Used for Treating Primar

Scope & coverage.

Types
  • Spironolactone
  • Eplerenone
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Chongqing Kerui Pharmaceutical
  • Jiangsu Chia Tai Fenghai Pharmaceutical
  • Grand Pharmaceutical
  • Yatai Pharma
  • Suzhou Homesun Pharmaceutical
  • Shanghai Xinyi Wanxiang pharmaceutical
  • Jiangsu Changjiang Pharmaceutical
  • Jiangsu Yunyang Pharmaceutical Group
  • Hangzhou Minsheng Pharmaceutical
  • Sinopharm Zhonglian Pharmaceutical
  • Zydus
  • Viatris Pharmaceuticals
  • Sun Pharmaceuticals
  • Sandoz
  • Pfizer
  • Mylan
  • MSN
  • Kyorin Rimedio
  • Camber Pharmaceuticals
  • Amneal Pharmaceuticals
  • Actavis Elizabeth
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs Used for Treating Primary Aldosteronism Market by Type
  3. 1.2.1 Global Drugs Used for Treating Primary Aldosteronism Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Spironolactone
  5. 1.2.3 Eplerenone
  6. 1.2.4 Other
  7. 1.3 Drugs Used for Treating Primary Aldosteronism Market by Application
  8. 1.3.1 Global Drugs Used for Treating Primary Aldosteronism Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital and Clinic
  10. 1.3.3 Pharmacy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drugs Used for Treating Primary Aldosteronism Market Dynamics
  1. 2.1 Drugs Used for Treating Primary Aldosteronism Industry Trends
  2. 2.2 Drugs Used for Treating Primary Aldosteronism Industry Drivers
  3. 2.3 Drugs Used for Treating Primary Aldosteronism Industry Opportunities and Challenges
  4. 2.4 Drugs Used for Treating Primary Aldosteronism Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Drugs Used for Treating Primary Aldosteronism Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Drugs Used for Treating Primary Aldosteronism Revenue by Region
  3. 3.2.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs Used for Treating Primary Aldosteronism Revenue by Region (2021-2026)
  5. 3.2.3 Global Drugs Used for Treating Primary Aldosteronism Revenue by Region (2027-2032)
  6. 3.2.4 Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Drugs Used for Treating Primary Aldosteronism Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Drugs Used for Treating Primary Aldosteronism Sales by Region
  9. 3.4.1 Global Drugs Used for Treating Primary Aldosteronism Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Region (2021-2026)
  11. 3.4.3 Global Drugs Used for Treating Primary Aldosteronism Sales by Region (2027-2032)
  12. 3.4.4 Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Manufacturers
  2. 4.1.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Drugs Used for Treating Primary Aldosteronism Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Manufacturers
  6. 4.2.1 Global Drugs Used for Treating Primary Aldosteronism Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Drugs Used for Treating Primary Aldosteronism Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Drugs Used for Treating Primary Aldosteronism Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Drugs Used for Treating Primary Aldosteronism Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Drugs Used for Treating Primary Aldosteronism Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Drugs Used for Treating Primary Aldosteronism Manufacturers, Product Type & Application
  13. 4.7 Global Drugs Used for Treating Primary Aldosteronism Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Drugs Used for Treating Primary Aldosteronism Market CR5 and HHI
  16. 4.8.2 2025 Drugs Used for Treating Primary Aldosteronism Tier 1, Tier 2, and Tier 3
5 Drugs Used for Treating Primary Aldosteronism Market by Type
  1. 5.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Type
  2. 5.1.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Type
  6. 5.2.1 Global Drugs Used for Treating Primary Aldosteronism Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Type (2021-2032)
  9. 5.3 Global Drugs Used for Treating Primary Aldosteronism Price by Type
6 Drugs Used for Treating Primary Aldosteronism Market by Application
  1. 6.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Application
  2. 6.1.1 Global Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Drugs Used for Treating Primary Aldosteronism Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Application
  6. 6.2.1 Global Drugs Used for Treating Primary Aldosteronism Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Drugs Used for Treating Primary Aldosteronism Sales Market Share by Application (2021-2032)
  9. 6.3 Global Drugs Used for Treating Primary Aldosteronism Price by Application
7 Company Profiles
  1. 7.1 Chongqing Kerui Pharmaceutical
  2. 7.1.1 Chongqing Kerui Pharmaceutical Company Information
  3. 7.1.2 Chongqing Kerui Pharmaceutical Business Overview
  4. 7.1.3 Chongqing Kerui Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chongqing Kerui Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  6. 7.1.5 Chongqing Kerui Pharmaceutical Recent Developments
  7. 7.2 Jiangsu Chia Tai Fenghai Pharmaceutical
  8. 7.2.1 Jiangsu Chia Tai Fenghai Pharmaceutical Company Information
  9. 7.2.2 Jiangsu Chia Tai Fenghai Pharmaceutical Business Overview
  10. 7.2.3 Jiangsu Chia Tai Fenghai Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Jiangsu Chia Tai Fenghai Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  12. 7.2.5 Jiangsu Chia Tai Fenghai Pharmaceutical Recent Developments
  13. 7.3 Grand Pharmaceutical
  14. 7.3.1 Grand Pharmaceutical Company Information
  15. 7.3.2 Grand Pharmaceutical Business Overview
  16. 7.3.3 Grand Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Grand Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  18. 7.3.5 Grand Pharmaceutical Recent Developments
  19. 7.4 Yatai Pharma
  20. 7.4.1 Yatai Pharma Company Information
  21. 7.4.2 Yatai Pharma Business Overview
  22. 7.4.3 Yatai Pharma Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Yatai Pharma Drugs Used for Treating Primary Aldosteronism Product Portfolio
  24. 7.4.5 Yatai Pharma Recent Developments
  25. 7.5 Suzhou Homesun Pharmaceutical
  26. 7.5.1 Suzhou Homesun Pharmaceutical Company Information
  27. 7.5.2 Suzhou Homesun Pharmaceutical Business Overview
  28. 7.5.3 Suzhou Homesun Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Suzhou Homesun Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  30. 7.5.5 Suzhou Homesun Pharmaceutical Recent Developments
  31. 7.6 Shanghai Xinyi Wanxiang pharmaceutical
  32. 7.6.1 Shanghai Xinyi Wanxiang pharmaceutical Company Information
  33. 7.6.2 Shanghai Xinyi Wanxiang pharmaceutical Business Overview
  34. 7.6.3 Shanghai Xinyi Wanxiang pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Shanghai Xinyi Wanxiang pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  36. 7.6.5 Shanghai Xinyi Wanxiang pharmaceutical Recent Developments
  37. 7.7 Jiangsu Changjiang Pharmaceutical
  38. 7.7.1 Jiangsu Changjiang Pharmaceutical Company Information
  39. 7.7.2 Jiangsu Changjiang Pharmaceutical Business Overview
  40. 7.7.3 Jiangsu Changjiang Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Changjiang Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  42. 7.7.5 Jiangsu Changjiang Pharmaceutical Recent Developments
  43. 7.8 Jiangsu Yunyang Pharmaceutical Group
  44. 7.8.1 Jiangsu Yunyang Pharmaceutical Group Company Information
  45. 7.8.2 Jiangsu Yunyang Pharmaceutical Group Business Overview
  46. 7.8.3 Jiangsu Yunyang Pharmaceutical Group Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Jiangsu Yunyang Pharmaceutical Group Drugs Used for Treating Primary Aldosteronism Product Portfolio
  48. 7.8.5 Jiangsu Yunyang Pharmaceutical Group Recent Developments
  49. 7.9 Hangzhou Minsheng Pharmaceutical
  50. 7.9.1 Hangzhou Minsheng Pharmaceutical Company Information
  51. 7.9.2 Hangzhou Minsheng Pharmaceutical Business Overview
  52. 7.9.3 Hangzhou Minsheng Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hangzhou Minsheng Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  54. 7.9.5 Hangzhou Minsheng Pharmaceutical Recent Developments
  55. 7.10 Sinopharm Zhonglian Pharmaceutical
  56. 7.10.1 Sinopharm Zhonglian Pharmaceutical Company Information
  57. 7.10.2 Sinopharm Zhonglian Pharmaceutical Business Overview
  58. 7.10.3 Sinopharm Zhonglian Pharmaceutical Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Sinopharm Zhonglian Pharmaceutical Drugs Used for Treating Primary Aldosteronism Product Portfolio
  60. 7.10.5 Sinopharm Zhonglian Pharmaceutical Recent Developments
  61. 7.11 Zydus
  62. 7.11.1 Zydus Company Information
  63. 7.11.2 Zydus Business Overview
  64. 7.11.3 Zydus Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Zydus Drugs Used for Treating Primary Aldosteronism Product Portfolio
  66. 7.11.5 Zydus Recent Developments
  67. 7.12 Viatris Pharmaceuticals
  68. 7.12.1 Viatris Pharmaceuticals Company Information
  69. 7.12.2 Viatris Pharmaceuticals Business Overview
  70. 7.12.3 Viatris Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Viatris Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio
  72. 7.12.5 Viatris Pharmaceuticals Recent Developments
  73. 7.13 Sun Pharmaceuticals
  74. 7.13.1 Sun Pharmaceuticals Company Information
  75. 7.13.2 Sun Pharmaceuticals Business Overview
  76. 7.13.3 Sun Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sun Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio
  78. 7.13.5 Sun Pharmaceuticals Recent Developments
  79. 7.14 Sandoz
  80. 7.14.1 Sandoz Company Information
  81. 7.14.2 Sandoz Business Overview
  82. 7.14.3 Sandoz Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Sandoz Drugs Used for Treating Primary Aldosteronism Product Portfolio
  84. 7.14.5 Sandoz Recent Developments
  85. 7.15 Pfizer
  86. 7.15.1 Pfizer Company Information
  87. 7.15.2 Pfizer Business Overview
  88. 7.15.3 Pfizer Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Pfizer Drugs Used for Treating Primary Aldosteronism Product Portfolio
  90. 7.15.5 Pfizer Recent Developments
  91. 7.16 Mylan
  92. 7.16.1 Mylan Company Information
  93. 7.16.2 Mylan Business Overview
  94. 7.16.3 Mylan Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Mylan Drugs Used for Treating Primary Aldosteronism Product Portfolio
  96. 7.16.5 Mylan Recent Developments
  97. 7.17 MSN
  98. 7.17.1 MSN Company Information
  99. 7.17.2 MSN Business Overview
  100. 7.17.3 MSN Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 MSN Drugs Used for Treating Primary Aldosteronism Product Portfolio
  102. 7.17.5 MSN Recent Developments
  103. 7.18 Kyorin Rimedio
  104. 7.18.1 Kyorin Rimedio Company Information
  105. 7.18.2 Kyorin Rimedio Business Overview
  106. 7.18.3 Kyorin Rimedio Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Kyorin Rimedio Drugs Used for Treating Primary Aldosteronism Product Portfolio
  108. 7.18.5 Kyorin Rimedio Recent Developments
  109. 7.19 Camber Pharmaceuticals
  110. 7.19.1 Camber Pharmaceuticals Company Information
  111. 7.19.2 Camber Pharmaceuticals Business Overview
  112. 7.19.3 Camber Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Camber Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio
  114. 7.19.5 Camber Pharmaceuticals Recent Developments
  115. 7.20 Amneal Pharmaceuticals
  116. 7.20.1 Amneal Pharmaceuticals Company Information
  117. 7.20.2 Amneal Pharmaceuticals Business Overview
  118. 7.20.3 Amneal Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Amneal Pharmaceuticals Drugs Used for Treating Primary Aldosteronism Product Portfolio
  120. 7.20.5 Amneal Pharmaceuticals Recent Developments
  121. 7.21 Actavis Elizabeth
  122. 7.21.1 Actavis Elizabeth Company Information
  123. 7.21.2 Actavis Elizabeth Business Overview
  124. 7.21.3 Actavis Elizabeth Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Actavis Elizabeth Drugs Used for Treating Primary Aldosteronism Product Portfolio
  126. 7.21.5 Actavis Elizabeth Recent Developments
  127. 7.22 Accord Healthcare
  128. 7.22.1 Accord Healthcare Company Information
  129. 7.22.2 Accord Healthcare Business Overview
  130. 7.22.3 Accord Healthcare Drugs Used for Treating Primary Aldosteronism Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Accord Healthcare Drugs Used for Treating Primary Aldosteronism Product Portfolio
  132. 7.22.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Drugs Used for Treating Primary Aldosteronism Market Size by Type
  2. 8.1.1 North America Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032)
  3. 8.1.2 North America Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032)
  4. 8.1.3 North America Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2032)
  5. 8.2 North America Drugs Used for Treating Primary Aldosteronism Market Size by Application
  6. 8.2.1 North America Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032)
  7. 8.2.2 North America Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032)
  8. 8.2.3 North America Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2032)
  9. 8.3 North America Drugs Used for Treating Primary Aldosteronism Market Size by Country
  10. 8.3.1 North America Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Drugs Used for Treating Primary Aldosteronism Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Drugs Used for Treating Primary Aldosteronism Market Size by Type
  2. 9.1.1 Europe Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032)
  3. 9.1.2 Europe Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032)
  4. 9.1.3 Europe Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2032)
  5. 9.2 Europe Drugs Used for Treating Primary Aldosteronism Market Size by Application
  6. 9.2.1 Europe Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032)
  7. 9.2.2 Europe Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032)
  8. 9.2.3 Europe Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2032)
  9. 9.3 Europe Drugs Used for Treating Primary Aldosteronism Market Size by Country
  10. 9.3.1 Europe Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Drugs Used for Treating Primary Aldosteronism Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Drugs Used for Treating Primary Aldosteronism Market Size by Type
  2. 10.1.1 China Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032)
  3. 10.1.2 China Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032)
  4. 10.1.3 China Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2032)
  5. 10.2 China Drugs Used for Treating Primary Aldosteronism Market Size by Application
  6. 10.2.1 China Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032)
  7. 10.2.2 China Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032)
  8. 10.2.3 China Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs Used for Treating Primary Aldosteronism Market Size by Type
  2. 11.1.1 Asia Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032)
  3. 11.1.2 Asia Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032)
  4. 11.1.3 Asia Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2032)
  5. 11.2 Asia Drugs Used for Treating Primary Aldosteronism Market Size by Application
  6. 11.2.1 Asia Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032)
  7. 11.2.2 Asia Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032)
  8. 11.2.3 Asia Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2032)
  9. 11.3 Asia Drugs Used for Treating Primary Aldosteronism Market Size by Country
  10. 11.3.1 Asia Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Drugs Used for Treating Primary Aldosteronism Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs Used for Treating Primary Aldosteronism Market Size by Type
  2. 12.1.1 SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Drugs Used for Treating Primary Aldosteronism Price by Type (2021-2032)
  5. 12.2 SAMEA Drugs Used for Treating Primary Aldosteronism Market Size by Application
  6. 12.2.1 SAMEA Drugs Used for Treating Primary Aldosteronism Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Drugs Used for Treating Primary Aldosteronism Price by Application (2021-2032)
  9. 12.3 SAMEA Drugs Used for Treating Primary Aldosteronism Market Size by Country
  10. 12.3.1 SAMEA Drugs Used for Treating Primary Aldosteronism Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Drugs Used for Treating Primary Aldosteronism Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Drugs Used for Treating Primary Aldosteronism Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Drugs Used for Treating Primary Aldosteronism Value Chain Analysis
  2. 13.1.1 Drugs Used for Treating Primary Aldosteronism Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Drugs Used for Treating Primary Aldosteronism Production Mode & Process
  6. 13.2 Drugs Used for Treating Primary Aldosteronism Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Drugs Used for Treating Primary Aldosteronism Distributors
  9. 13.2.3 Drugs Used for Treating Primary Aldosteronism Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst